NVST

insider transactions

Envista Holdings Corp — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-9.7K

0 buy · 9.7K sell

Net value · 365d

-$290.2K

$0 in · $290.2K out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 9.7K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Other·F
May 25, 26

Keel Paul A KEY

Chief Executive Officer

$300.2K

12.8K sh · $23.43

Own -3%
Grant·A
May 19, 26

James Andrew Pierce

Director

$0

9.3K sh

Own +102%
Grant·A
May 19, 26

Vivek Jain

Director

$0

9.3K sh

Own +21%
Grant·A
May 19, 26

Scott R Huennekens

Director

$0

12.6K sh

Own +18%
Grant·A
May 19, 26

Kieran Gallahue

Director

$0

9.3K sh

Own +21%
Grant·A
May 19, 26

Daniel Raskas

Director

$0

9.3K sh

Own +21%
Grant·A
May 19, 26

Christine A Tsingos

Director

$0

9.3K sh

Own +18%
Grant·A
May 19, 26

Wendy Carruthers

Director

$0

9.3K sh

Own +18%
Grant·A
Feb 25, 26

Stefan Nilsson KEY

President, Nobel Biocare

$0

18.0K sh

Own New
Grant·A
Feb 25, 26

Stefan Nilsson KEY

President, Nobel Biocare

$0

13.8K sh

Own New
Grant·A
Feb 25, 26

Stefan Nilsson KEY

President, Nobel Biocare

$0

7.6K sh

Own +14%
Other·F
Feb 25, 26

Stefan Nilsson KEY

President, Nobel Biocare

$5.4K

182 sh · $29.59

Own -0%
Grant·A
Feb 25, 26

Faez C Kaabi

Chief Accounting Officer

$0

13.5K sh

Own +30%
Other·F
Feb 25, 26

Faez C Kaabi

Chief Accounting Officer

$146.9K

5.0K sh · $29.59

Own -10%
Grant·A
Feb 25, 26

Mischa Reis

SVP, Strategy & Bus. Dev.

$0

14.0K sh

Own New
Grant·A
Feb 25, 26

Mischa Reis

SVP, Strategy & Bus. Dev.

$0

10.8K sh

Own New
Grant·A
Feb 25, 26

Mischa Reis

SVP, Strategy & Bus. Dev.

$0

5.9K sh

Own +20%
Other·F
Feb 25, 26

Mischa Reis

SVP, Strategy & Bus. Dev.

$88.1K

3.0K sh · $29.59

Own -9%
Grant·A
Feb 25, 26

Mark E Nance

General Counsel

$0

30.0K sh

Own New
Grant·A
Feb 25, 26

Mark E Nance

General Counsel

$0

23.1K sh

Own New
Grant·A
Feb 25, 26

Mark E Nance

General Counsel

$0

12.7K sh

Own +18%
Other·F
Feb 25, 26

Mark E Nance

General Counsel

$99.7K

3.4K sh · $29.59

Own -5%
Grant·A
Feb 25, 26

Keel Paul A KEY

Chief Executive Officer

$0

115.3K sh

Own New
Grant·A
Feb 25, 26

Keel Paul A KEY

Chief Executive Officer

$0

132.9K sh

Own New
Grant·A
Feb 25, 26

Keel Paul A KEY

Chief Executive Officer

$0

48.7K sh

Own +14%
Other·F
Feb 25, 26

Keel Paul A KEY

Chief Executive Officer

$350.3K

11.8K sh · $29.59

Own -3%
Grant·A
Feb 25, 26

Eric D. Hammes KEY

Chief Financial Officer

$0

38.0K sh

Own New
Grant·A
Feb 25, 26

Eric D. Hammes KEY

Chief Financial Officer

$0

29.2K sh

Own New
Grant·A
Feb 25, 26

Eric D. Hammes KEY

Chief Financial Officer

$0

16.1K sh

Own +17%
Other·F
Feb 25, 26

Eric D. Hammes KEY

Chief Financial Officer

$60.5K

2.0K sh · $29.59

Own -2%
Grant·A
Feb 25, 26

Robert Befidi KEY

President, Diagnostics

$0

18.0K sh

Own New
Grant·A
Feb 25, 26

Robert Befidi KEY

President, Diagnostics

$0

13.8K sh

Own New
Grant·A
Feb 25, 26

Robert Befidi KEY

President, Diagnostics

$0

7.6K sh

Own +18%
Other·F
Feb 25, 26

Robert Befidi KEY

President, Diagnostics

$64.4K

2.2K sh · $29.59

Own -5%
Grant·A
Feb 25, 26

Veronica Acurio KEY

President, Orthodontics

$0

18.0K sh

Own New
Grant·A
Feb 25, 26

Veronica Acurio KEY

President, Orthodontics

$0

13.8K sh

Own New
Grant·A
Feb 25, 26

Veronica Acurio KEY

President, Orthodontics

$0

7.6K sh

Own +16%
Other·F
Feb 25, 26

Veronica Acurio KEY

President, Orthodontics

$41.8K

1.4K sh · $29.59

Own -3%
Exercise·M
Feb 10, 26

Mischa Reis

SVP, Strategy & Bus. Dev. · 10b5-1

$0

5.6K sh

Own New
Exercise·M
Feb 10, 26

Mischa Reis

SVP, Strategy & Bus. Dev. · 10b5-1

$0

4.0K sh

Own New
Sell·S
Feb 10, 26

Mischa Reis

SVP, Strategy & Bus. Dev. · 10b5-1

$169.0K

5.6K sh · $30.00

Own -15%
Exercise·M
Feb 10, 26

Mischa Reis

SVP, Strategy & Bus. Dev. · 10b5-1

$90.0K

5.6K sh · $15.97

Own +17%
Sell·S
Feb 10, 26

Mischa Reis

SVP, Strategy & Bus. Dev. · 10b5-1

$121.2K

4.0K sh · $30.00

Own -11%
Exercise·M
Feb 10, 26

Mischa Reis

SVP, Strategy & Bus. Dev. · 10b5-1

$76.9K

4.0K sh · $19.04

Own +12%
Grant·A
Feb 1, 26

Faez C Kaabi

Chief Accounting Officer

$27.8K

1.2K sh · $23.47

Own +31%
Grant·A
Feb 1, 26

Mischa Reis

SVP, Strategy & Bus. Dev.

$63.4K

2.9K sh · $21.71

Own +11%
Grant·A
Feb 1, 26

Mark E Nance

General Counsel

$47.1K

2.0K sh · $23.47

Own +36%
Grant·A
Feb 1, 26

Keel Paul A KEY

Chief Executive Officer

$96.0K

4.1K sh · $23.47

Own New
Grant·A
Feb 1, 26

Eric D. Hammes KEY

Chief Financial Officer

$26.3K

1.1K sh · $23.47

Own New
Grant·A
Feb 1, 26

Robert Befidi KEY

President, Diagnostics

$23.4K

998 sh · $23.47

Own +87%
Grant·A
Feb 1, 26

Veronica Acurio KEY

President, Orthodontics

$23.4K

998 sh · $23.47

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
May 25, 2026	Keel Paul A KEY	Chief Executive Officer	Other F	12.8K	-3%	$23.43	$300.2K
May 19, 2026	James Andrew Pierce	Director	Grant A	9.3K	+102%	—	$0
May 19, 2026	Vivek Jain	Director	Grant A	9.3K	+21%	—	$0
May 19, 2026	Scott R Huennekens	Director	Grant A	12.6K	+18%	—	$0
May 19, 2026	Kieran Gallahue	Director	Grant A	9.3K	+21%	—	$0
May 19, 2026	Daniel Raskas	Director	Grant A	9.3K	+21%	—	$0
May 19, 2026	Christine A Tsingos	Director	Grant A	9.3K	+18%	—	$0
May 19, 2026	Wendy Carruthers	Director	Grant A	9.3K	+18%	—	$0
Feb 25, 2026	Stefan Nilsson KEY	President, Nobel Biocare	Grant A	18.0K	New	—	$0
Feb 25, 2026	Stefan Nilsson KEY	President, Nobel Biocare	Grant A	13.8K	New	—	$0
Feb 25, 2026	Stefan Nilsson KEY	President, Nobel Biocare	Grant A	7.6K	+14%	—	$0
Feb 25, 2026	Stefan Nilsson KEY	President, Nobel Biocare	Other F	182	-0%	$29.59	$5.4K
Feb 25, 2026	Faez C Kaabi	Chief Accounting Officer	Grant A	13.5K	+30%	—	$0
Feb 25, 2026	Faez C Kaabi	Chief Accounting Officer	Other F	5.0K	-10%	$29.59	$146.9K
Feb 25, 2026	Mischa Reis	SVP, Strategy & Bus. Dev.	Grant A	14.0K	New	—	$0
Feb 25, 2026	Mischa Reis	SVP, Strategy & Bus. Dev.	Grant A	10.8K	New	—	$0
Feb 25, 2026	Mischa Reis	SVP, Strategy & Bus. Dev.	Grant A	5.9K	+20%	—	$0
Feb 25, 2026	Mischa Reis	SVP, Strategy & Bus. Dev.	Other F	3.0K	-9%	$29.59	$88.1K
Feb 25, 2026	Mark E Nance	General Counsel	Grant A	30.0K	New	—	$0
Feb 25, 2026	Mark E Nance	General Counsel	Grant A	23.1K	New	—	$0
Feb 25, 2026	Mark E Nance	General Counsel	Grant A	12.7K	+18%	—	$0
Feb 25, 2026	Mark E Nance	General Counsel	Other F	3.4K	-5%	$29.59	$99.7K
Feb 25, 2026	Keel Paul A KEY	Chief Executive Officer	Grant A	115.3K	New	—	$0
Feb 25, 2026	Keel Paul A KEY	Chief Executive Officer	Grant A	132.9K	New	—	$0
Feb 25, 2026	Keel Paul A KEY	Chief Executive Officer	Grant A	48.7K	+14%	—	$0
Feb 25, 2026	Keel Paul A KEY	Chief Executive Officer	Other F	11.8K	-3%	$29.59	$350.3K
Feb 25, 2026	Eric D. Hammes KEY	Chief Financial Officer	Grant A	38.0K	New	—	$0
Feb 25, 2026	Eric D. Hammes KEY	Chief Financial Officer	Grant A	29.2K	New	—	$0
Feb 25, 2026	Eric D. Hammes KEY	Chief Financial Officer	Grant A	16.1K	+17%	—	$0
Feb 25, 2026	Eric D. Hammes KEY	Chief Financial Officer	Other F	2.0K	-2%	$29.59	$60.5K
Feb 25, 2026	Robert Befidi KEY	President, Diagnostics	Grant A	18.0K	New	—	$0
Feb 25, 2026	Robert Befidi KEY	President, Diagnostics	Grant A	13.8K	New	—	$0
Feb 25, 2026	Robert Befidi KEY	President, Diagnostics	Grant A	7.6K	+18%	—	$0
Feb 25, 2026	Robert Befidi KEY	President, Diagnostics	Other F	2.2K	-5%	$29.59	$64.4K
Feb 25, 2026	Veronica Acurio KEY	President, Orthodontics	Grant A	18.0K	New	—	$0
Feb 25, 2026	Veronica Acurio KEY	President, Orthodontics	Grant A	13.8K	New	—	$0
Feb 25, 2026	Veronica Acurio KEY	President, Orthodontics	Grant A	7.6K	+16%	—	$0
Feb 25, 2026	Veronica Acurio KEY	President, Orthodontics	Other F	1.4K	-3%	$29.59	$41.8K
Feb 10, 2026	Mischa Reis 10b5-1	SVP, Strategy & Bus. Dev.	Exercise M	5.6K	New	—	$0
Feb 10, 2026	Mischa Reis 10b5-1	SVP, Strategy & Bus. Dev.	Exercise M	4.0K	New	—	$0
Feb 10, 2026	Mischa Reis 10b5-1	SVP, Strategy & Bus. Dev.	Sell S	5.6K	-15%	$30.00	$169.0K
Feb 10, 2026	Mischa Reis 10b5-1	SVP, Strategy & Bus. Dev.	Exercise M	5.6K	+17%	$15.97	$90.0K
Feb 10, 2026	Mischa Reis 10b5-1	SVP, Strategy & Bus. Dev.	Sell S	4.0K	-11%	$30.00	$121.2K
Feb 10, 2026	Mischa Reis 10b5-1	SVP, Strategy & Bus. Dev.	Exercise M	4.0K	+12%	$19.04	$76.9K
Feb 1, 2026	Faez C Kaabi	Chief Accounting Officer	Grant A	1.2K	+31%	$23.47	$27.8K
Feb 1, 2026	Mischa Reis	SVP, Strategy & Bus. Dev.	Grant A	2.9K	+11%	$21.71	$63.4K
Feb 1, 2026	Mark E Nance	General Counsel	Grant A	2.0K	+36%	$23.47	$47.1K
Feb 1, 2026	Keel Paul A KEY	Chief Executive Officer	Grant A	4.1K	New	$23.47	$96.0K
Feb 1, 2026	Eric D. Hammes KEY	Chief Financial Officer	Grant A	1.1K	New	$23.47	$26.3K
Feb 1, 2026	Robert Befidi KEY	President, Diagnostics	Grant A	998	+87%	$23.47	$23.4K
Feb 1, 2026	Veronica Acurio KEY	President, Orthodontics	Grant A	998	New	$23.47	$23.4K

About NVST insider trading

This page tracks insider transactions for Envista Holdings Corp (NVST) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.